Skip to main content
. 2016 Feb 12;39(3):323–329. doi: 10.2337/dc15-1649

Figure 1.

Figure 1

Example of a multi-agent study design of early combination therapies of pediatric T2D modeled after the TODAY study. DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; SGLT2, sodium–glucose cotransporter 2.